LAVA Therapeutics N.V. Ordinary Shares Share Price
LVTXLAVA Therapeutics N.V. Ordinary Shares Stock Performance
Open $1.59 | Prev. Close $1.61 | Circuit Range N/A |
Day Range $1.59 - $1.61 | Year Range $0.85 - $2.00 | Volume 872 |
Average Traded $1.60 |
LAVA Therapeutics N.V. Ordinary Shares Share Price Chart
About LAVA Therapeutics N.V. Ordinary Shares
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
LAVA Therapeutics N.V. Ordinary Shares Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Nov-25 | $1.59 | $1.61 | +0.00% |
12-Nov-25 | $1.59 | $1.61 | +0.00% |
11-Nov-25 | $1.61 | $1.61 | +0.00% |
10-Nov-25 | $1.61 | $1.61 | -0.31% |
05-Nov-25 | $1.61 | $1.61 | +0.94% |
03-Nov-25 | $1.60 | $1.60 | -1.23% |
31-Oct-25 | $1.62 | $1.62 | +0.00% |